DALLAS (Reuters) - A blood clot preventer sold by Bristol-Myers Squibb Corp. and Sanofi-Aventis was inferior to the most commonly used blood thinner for the prevention of stroke in patients with irregular heart rhythm, according to a study presented on Monday.